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Effects of Cigarette Smoking on Metabolic
Events in the Lung
by Satoshi Kitamura*
Nicotine and cigarette smoke extract show acute physiological effects: increasing tracheal pressure (PTR),
pulmonary artery pressure (PPA), systemic blood pressure (PyT), and left atrium pressure (PLA); and de-
creasing cardiac output (4AORTA) and blood flow to the left lower lobe(1L). In addition, cigarette smoking
induces bronchoconstriction, thus decreasing peak flow, FVC, and FEVY.o in healthy subjects. It has also
been demonstrated that cigarette smoking caused temporary slowing of mucociliary clearance in the lung
and that cigarette smoke increases the activity of aryl hydrocarbon hydroxylase which metabolizes
benzo[a]pyrene. We demonstrated that serum angiotensin I converting enzyme (ACE) activity showed a
significant increase immediately after smoking and returned to the control level 20 min after smoking. We
also demonstrated that plasma histamine levels showed a marked decrease after smoldng. Furthermore, the
effects of cigarette smoke and related substances on prostaglandin, thromboxane, testosterone, cyclic nu-
cleotides metabolism, and protein synthesis were also investigated.
Introduction
Cigarette smoke contains hundreds ofgaseous and par-
ticulate constituents, many of which are cytotoxins (1).
The adverse physiological and biochemical effects exerted
bycigarette smoke on anactive smokerhavebeen alluded
to, if not clearly demonstrated. Cigarette smoldng is an
important risk factor in lung cancer, chronic obstructive
lung disease, and coronary heart disease (2,3).
The fundamental importance of the lung in providing
oxygen and elininating carbon dioxide is well known.
However, the lung has an another important role-the
metabolism ofvasoactive substances (4). In this brief re-
view, the effectsofcigarette smoking onvariousmetabolic
events in the lung in vitro and in vivo are presented.
Cardiopulmonary Effects of
Tobacco and Related Substances
Effects of Nicotine and Cigarette Smoke
Extract Injection on the Canine Airway
and Pulmonary and Systemic Circulation
(5)
It is well known that cigarette smoldng has diverse
effects not only on the airway system but also on the
pulmonary and systemic circulatory system. The acute
effects of cigarette smoking are induced mainly by nico-
tine, the main alkaloid in tobacco. This investigation was
conducted to explore the acute effects ofnicotine and cig-
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arette smoke extract on canine airway, pulmonary, and
systemicdrculatorysystemsinvivo. Twelvedogs, weigh-
ing between 18 and 25 kg, were anesthetized with intra-
venous adminstration of25 mg/kg of sodium pentobarbi-
tal. The trachea of each dog was cannulated for artificial
ventilation with a volume-type Harvard respirator, and
the left femoral artery and vein were catheterized for
measurement ofsystemic blood pressure (PsYsT), and for
infusing drugs such as heparin Na (100 U/kg) or succinyl
choline chloride (2%o, 0.2 mL/kg/hr). The left hemithorax
was opened under artificial respiration, and catheters
were inserted into the pulmonary artery trunk and left
atrium for measurement of pulmonary artery pressure
(PPA) and leftatrium pressure(PLA). Thenoncannulating
electromagnetic flow probes were placed around the as-
cending aorta and pulmonary arteryofthe left lowerlobe
for measurement of cardiac output (QAORTA) and blood
flow to the left lower lobe (QLLL), respectively. Tracheal
pressure (PTR) wasmeasured atthe orifice ofthetracheal
cannula using a pressure transducer. Nicotine and ciga-
rette-smoke extractwereinjected intothe left pulmonary
artery through a polyethylene catheter using a Harvard
lowspeedinfusionpump. PTR, PPA,PLA, PSYST, QAORTA,
and QLLL were recorded and displayed on an electric po-
lyrecorder (Nihon Kohden, Japan) through an amplifier.
Figure 1 illustrates the experimental arrangement. The
saline solution of cigarette smoke extract was prepared
by smoldng a cigarette (Hilite, one of the popular ciga-
rettes manufactured bytheJapan Monopoly Corporation)
through an aqua-filter containing 2 mL of water and di-
luted with 20 mL ofsaline.
Figure 2 is a typical record of various paraneters
changed by an injection ofnicotine solution into the pul-S. KITAMURA
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FIGURE 1. Experimental arrangement showing positioning of
probes for the measurement ofpulmonary artery pressure (PPA),
left atrium pressure (PLA), systemic blood pressure (PsysT), car-
diac output (QAO TA), tracheal pressure (PTR), and blood flow to
left lower lobe (Q~LLL). Drugs were infused through the femoral
vein and left pulmonary artery as indicated.
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FIGURE 2. A typical record of various parameters changed by an
injection ofnicotine solution into the pulmonary artery ofthe left
lower lobe in an anesthetized dog.
monary artery of the left lower lobe in an anesthetized
dog. Injection of nicotine (50 ig/kg) induced a transient
increase ofPTR; asharp increase ofPPAfollowing aninitial
slight decrease; an increase ofPLA; a marked increase of
PSYST; and a decrease of QAORTA and QLLL followed by
slight increases. The lower dose (10 jig/kg) of nicotine
showed almost the same tendency. Figure 3 shows
changes of PPA, PLA, and PSYST by injection of various
doses of nicotine into the pulmonary artery of the left
lower lobe. It is obvious from this figure that PPA, PLA,
and PSYST showed a marked increase in their dose-de-
pendence.
Figure 4 is the summary of experimental data from
eight dogs, showing changes in PTR, PPA, and PSYST with
increasing doses of nicotine. PPA and PSYST showed sig-
nificant increases in their dose-dependence, while PTR
tendedtoincrease butwithoutsignificant differences (Stu-
dent's unpaired t- test).
Figure 5 is the summary of experimental data from
eight dogs showing changes in PLA, QAORTA, and QLLL
withincreasingdosesofnicotine. PLAshowed asignificant
increased dose-dependence, while QAORTA and QLLL
showed significant decreases in their dose-dependence.
Figure 6 is a typical record of various parameters
changed by an injection of2 mL ofsaline solution of cig-
arette smoke extract into the pulmonary artery ofthe left
lower lobe in an anesthetized dog. Injection of cigarette
smoke extract solution elicited a slight increase of PPR;
an increase of PPA following an initial slight.decrease; a
marked increase ofPSYST; and decreases of QAORTA and
QLLL followed by increases. The results suggest that ni-
cotine and cigarette smoke extract show acute physiolog-
ical effects increasing PTR, PPA, and PSYST, and decreas-
ing QAORTA and QLLL.
Effects of Cigarette Smoking on
Pulmonary Functions in Healthy
Volunteers (6)
Twenty-three healthy nonasthmatic volunteers (20 men
and 3 women) were studied. They ranged in age from 22
to 47years, averaging 33.3 years. All ofthem were heavy
smokers (20-40 cigarettes/day) for 5 to 20 years. The
volunteers stopped smoking at least 12 hr before testing
began. When testing began, men smoked five cigarettes,
and women smoked three cigarettes within 10 min. Men
smoked more cigarettes than women to account for the
lowerbodyweightofthewomen(10-15kglessthanmen).
Several ofthe volunteers showed symptoms such as diz-
ziness or palpitation. Peak flow, forced vital capacity
(FVC), and one-second forced expiratory volume
(FEV1.0) were measured before, immediately after, and
20 min after smoking. Cigarettes used in this experiment
were Hilite, made byJapan Monopoly Corporation.
Figure 7 shows the effect ofcigarette smoking on peak
flow. Mean values and standard deviations of peak flow
before, immediately after, and 20 min after cigarette
smoldng were 568.05 + 88.62 L/min, 543.13 + 88.04 L/
min, and 569.06 + 93.55 L/min, respectively. Figure 8
shows the effect ofcigarette smoking on FVC. Mean val-
ues and standard deviations ofFVC before, immediately
after, and 20 min after cigarette smoking were 4233.16
+ 658.03 mL, 3964.21 ± 65.00mL, and4041.05 + 688.18
mL, respectively.
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FIGURE 3. Changes ofPPA, PLA, and PSYST by injections of nicotine into the pulmonary artery ofthe left lower lobe.
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FIGURE 4. Percentage change ofPTR, PPA. and PSYSTby injections
ofnicotine into the pulmonary artery ofthe left lower lobe. * p <
20.02, ** p < 0.01, *** p < 0.001.
Figure 9 shows the effect of cigarette smoldng on
FEV1.0. Mean values and standard deviations ofFEV1.0
before, immediately after, and 20 min after cigarette
smoldng were 3734.74 + 658.60 mL, 3515.26 + 683.82
mL, and 3476.84 ± 556.8 mL, respectively.
These results suggest that cigarette smoking induces
bronchoconstriction, thusdecreasingpeakflow, FVC, and
FEV1.0. Da Silva et al. (7) studied the effect ofsmoldng
one cigarette on lungfunction in 21 healthy subjects. Air-
way resistance, measured by body plethysmography, in-
creased in 19 patients. Closing volume was not signifi-
cantly changed after smoking one cigarette, although the
maximum expiratory flow at 50% of the vital capacity
(MEF50) decreased significantly. These findings indicate
that smoldng one cigarette dose notincrease small airway
resistance measurably when procedures not requiring
maxmum expiratory flow are used. On the other hand,
the decrease of MEF50 indicates that airways upstream
from the flow-limiting segment have increased resistance
aftersmokingonecigarette, sincenochangesintheelastic
properties ofthe lung were demonstrated.
-40'
** _
J+ * **** **
**
**
N =8
o 2.5 5 10 15 20
Nicotine(ug/kg)
25 5b
FIGURE 5. Percentage change of PLA, QAORTA, and QLLL by injec-
tions ofnicotine into the pulmonary artery ofthe left lower lobe.
* p <0.02, ** p <0.01, ***p <0.001.
Effect of Cigarette Smoke on Mucociliary
Clearance and on Phagocyte Function
Theciliastatic effectofcigarette smoke andsmokecom-
ponents has been demonstrated by direct observation of
the tracheal mucosa in a variety ofanials including the
cow, rabbit (8), and cat (9). Mucodiliary transport rates
have been measured in the human nose, but few data on
the effects of cigarette smoke have been reported (10).
Frances et al. (11) studied the effects ofwhole cigarette
smoke on the transport of particles on the nasociiary
mucosaofthedonkey. Theyconcludedthatthenasociliary
mucosawas much more resistant to cigarette smoke than
the tracheobronchial tree, since previous experiments on
donkeys (12) demonstrated that exposure to the smoke
from 20 cigarettes produced amarked retardation in par-
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FIGURE 6. A typical record of various parameters changed by an
injection of saline solution of cigarette smoke extract into the
pulmonary artery ofthe left lower lobe in an anesthetized dog.
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FIGURE 7. Effect ofcigarette smoking onpeak flow. Control values
were measured before cigarette smoking. 0 min measurements
were taken immediately after cigarette smoking.
ticle transport in the trachea. Pavia et al. (13) demon-
strated that tobacco smoking caused temporary slowing
of mucociJiary clearance in the lung. In brief, clearance
was assessed by monitoring, extemally to the chest, the
removal of 5 ,um particles labeled with technetiumn-99mn
which had been inhaled in controlled conditions in 22 vol-
unteers (aged 64-92; mean 74.6years) fromhomes forthe
elderly.
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FIGURE 9. Effect of cigarette smoking on FEV1.0.
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Acute exposure to cigarette smoke has been shown to
inhibit the bactericidal activity of alveolar macrophages
cultured in ?itro (14,15) and the ability ofmouse alveolar
macrophages to phagocytose inhaled particles (16). How-
ever, the effect of chronic inhalation of cigarette smoke
on bactexicidal and phagocytic activities has not been elu-
cidated yet. When investigations were conducted using
alveolar macrophages recovered from cigarette smokers
and nonsmokers bybronchoalveolarlavage (17-19), itwas
found that cigarette smokers had a higher number ofal-
veolarmacrophages andthattheirmacrophages generally
had a normal level ofphagocytic activity.
Warr et al. (20) demonstrated that pulmonary alveolar
macrophages from six cigarette smokers showed higher
random migration and greater chemotactic responsive-
ness to casein than did macrophages from seven nons-
mokers and suggested thatpulmonarymacrophages were
metabolically activated by cigarette smoldng. This might
indicate that cigarette smokers, because oftheir elevated
levels of alveolar macrophages, possess a more effective
pulmonary phagocytic ability than nonsmokers. Rylander
(21,22) found that guinea pigs exposed to cigarette smoke
for 4 weeks developed an increased number of alveolar
macrophages and pulmonary polymorphonuclear leuko-
cytes, butthebactericidal activity ofthese cells measured
insitu wasmarkedly depressed. Because oftherelatively
high number ofpulmonary polymorphonuclear leukocytes
in guinea pigs and the relatively short period ofcigarette
smoke exposure used for these investigations, it is sug-
gested that these experimental conditions might differ
from the situation in the lungs ofcigarette smokers.
Demarest et al. (23) investigated the effects of acute
smoke inhalation on the random and chemotactic migra-
tion ofhuman pulmonary alveolar macrophages (AM) ob-
tained byfiberoptic subsegmental pulmonary lavage in 19
nonsmokers and 7 smokers. He demonstrated the invtitro
exposure of pulmonary AM to nontoxic doses of smoke
produced the impairment of AM chemotaxis and sug-
gested that these findings may partially explain the en-
hanced susceptibility of smokers to pulmonary infection.
The nylon fiber adherence in vitro ofAM from cigarette
smokers was uniformly decreased. Rasp et al. (24) dem-
onstrated that there is areversible, intrinsic defect in the
structure and adherence of AM from cigarette smokers
thatmayinfluencetheirfunctionandmayaccount, inpart,
for the increased yield of AM from the lavage fluid of
cigarette smokers.
Thomas et al. (25) investigated the phagocytic function
in mice chronically exposed to cigarette smoke, and the
effects of in vitro exposure to cigarette smoke on mac-
rophage activity. Cultures of radiolabeled Pseudonas
aeruginosa were employed to investigate phagocyte ac-
tivityinvivoandinvitro. Micewereexposedonweekdays
to fresh cigarette smoke for periods up to 37 weeks, and
the bactericidal and clearance activity oftheirlungs were
measured. Both pulmonary clearance and bactericidal ac-
tivity were impaired. They concluded that macrophages
exposed to cigarette smoke in vitro initially had a de-
pressed phagocytic rate, but if phagocytosis over a pro-
longed period was measured, it was eventually enhanced
overtherateofcontrolmacrophages, andthevaporphase
ofcigarette smoke could also transiently inhibit and then
enhance the phagocytic activity. Huber et al. (26) sug-
gested that chronic exposure to tobacco smoke does not
impair, and in fact may stimulate, the host defenses of
the lung, as evaluated by in vivo and in vitro pulmonary
AM function.
In contrast, Drath et al. (27) found that 30 days of
exposure to tobacco smoke caused an initial enhancement
ofphagocytic activitywhichwas laterreversedwithmore
chronic exposure, and finally, there was a definite inhi-
bitionofuptake. Thismayindicatethattheeffectofsmoke
on phagocytosis is cumulative.
Inaninvitrophagocyticsystemusingrabbitpulmonary
AM, small amounts of cigarette smoke quantitatively in-
hibited the capacity of the cells to inactivate Staphylo-
coccus albus bacteria. It is suggested that the role of
cigarette smokeinthepathogenesisofpulmonarydiseases
may be mediated through an inhibition ofthe phagocytic
activity ofAM (28).
The increase in secretion of lysozyme in macrophages
frombothhumansandrodentsexposedtosmokehasbeen
reported. This increase is associated with the production
of new lysosomes and not just an increase in enzyme
content within the original lysosomes (29). Macrophages
exposed to cigarette smoke also contain less succinate
dehydrogenase, cytochrome oxidase, acid phosphatase,
NADH diaphorase, and nonspecific esterase and have an
impaired ability to synthesize protein (30). Not oniy do
smokers have a greater number ofmacrophages, but the
cells also produce greater quantities ofelastase (31). The
secretion ofsuch enzymes may lead to subsequent tissue
damage and connective tissue degradation (32). Human
macrophages from smokers also release increased
amounts of 02 (superoxide anion). Such stimulation may
be a significant factor in the pathogenesis ofemphysema.
Cigarette smoke produces approximately a twofold in-
crease in oxygen consumption and hydrogen peroxide re-
leaseinresponsetophagocytosis. Studieshavealsoshown
that macrophages from smokers have a significantly
higherarylhydrocarbon hydroxylase activitythan similar
cells from nonsmokers (33,34). This increased enzyme ac-
tivity is important, since this enzyme system can metab-
olize polycyclic aromatic hydrocarbons tomore active car-
cinogens.
Effects of Tobacco and Related
Substances on Metabolic Events in
the Lung
Uptake and Metabolism of Nicotine by the
Lung
Tobacco smokers commonly inhale smoke into their
lungs, fromwhich some ofthe smokecomponents trans-
fer to the blood. Although components such as nicotine
transfer from lung tissue to the circulation extremely
rapidly, it is important to elucidate whether the lung
plays an active part in the fate and subsequent distri-
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bution ofthese components. The lung is the first organ
in the body to come into contact with nicotine inhaled
in tobacco smoke, and thus the possibility exists that a
first-pass pulmonary metabolism of nicotine could be
occurring which would be analogous to the first-pass
liver metabolism of orally administered drugs such as
lidocaine (35) and aspirin (36) in humans. Ifsuch a phe-
nomenon did occur, the effective dose ofnicotine reach-
ing the systemic circulation could be lowered, but then
the metabolites ofnicotine would be expected to reach
the systemic system and could cause adverse health
effect. Hoffman et al. (37) recently presented data that
clearly illustrate that from nicotine a number of nitro-
samines can be found including N'-nitrosonornicotine/
nicotine-derived nitrosaminoketone, which are strong
carcinogens.
In order to investigate the possibility of pulmonary
first-pass metabolism of nicotine inhaled in tobacco
smoke, McGovern et al. (38) studied the absorption and
disposition of "4C-nicotine in anisolated perfused rabbit
lung preparation after nicotine administration directly
into the perfusing blood and tobacco smoke administra-
tion via the inspired tracheal air. After administration
into the perfusing medium, the rate ofnicotine metab-
olism was first-order and dose-independent at the two
doses studied (0.1 and 1.0mg), butlungmetabolic clear-
ance was quite low (3 mL/min) relative to whole body
clearance (140 mL/min), measured by administering
14C- nicotine to intact rabbits. Accumulation ofnicotine
in the lung was 13 to 23% of the dose administered.
After administration of tobacco smoke from 14C-nico-
tine-spiked cigarettes, absorption ofnicotine wasrapid,
but the rate ofmetabolism was markedly reduced com-
pared with the studies in which the drug was admin-
istered in the perfusing medium. This reduction in the
rateofmetabolism wasapparently causedbysome com-
ponent of tobacco smoke; McGovern et al. concluded
that the slow clearance of nicotine by the rabbit lung,
which was further reduced after smoke administration
despite ahigh pulmonary blood flow rate made the pos-
sibility ofsignificantfirst-passlungmetabolismin smok-
ers unlikely.
Turner et al. (39) investigated metabolism ofnicotine
by the isolated perfused dog lung. 14C-nicotine (50 ,ug
every 30 sec for 10 min administered viathe pulmonary
artery) undergoes first-pass metabolism to a small ex-
tent. 14C-cotinine was detected in the venous blood. Of
the injected activity, 6% was in the lung at the end of
experiment, 60% beingpresent as'4C-nicotine, and20%
as 4C-nicotine-l'-oxide. But when 14C-nicotine was ad-
ministered in cigarette smoke, a greater degree ofme-
tabolism was observed at first-pass. Pyrolysis products
of 14C- nicotine also were present in the venous blood.
Lungs after smoke exposure contained 30% of admin-
istered radioactivity, with a substantial proportion of
"4C-nicotine-1'-oxide. Administration of14C-nicotine-la-
beled smoke-to-lung preparations, on closed circuit,
gave significant amounts of 14C-cotinine and other me-
tabolites over a 2 hr period. Lung tissue contained ap-
proximately 40% of injected dose of which 25% was
14C-nicotine. Large proportions of14C-cotinine and 14C0
nicotine-1'-oxide were present, but 45% ofthe activity
was present as other unidentified pyrolysis products.
Turner et al. (39) demonstrated the usefulness of the
isolated lungperfusion technique as a tool forthe study
ofthe metabolism ofsmoke constituents and illustrated
the importance of inhalation administration when as-
sessingthe capability oflungtissue tometabolize drugs
whose normal routes ofentry into the organism are via
the respiratory tract.
Effects of Cigarette Smoke on the
Metabolism of Benzo[a]Ipyrene by the
Lung
Smoking is an important risk factor in lung cancer,
which is most oftenbronchogenic. Cigarette smoke con-
tains many carcinogenic compounds such as
benzo[a]pyrene, which have to be metabolically acti-
vated in order to exert their carcinogenic effects (1).
Benzo[a]pyrene is metabolizedbyarylhydrocarbon hy-
droxylase to epoxides, which can be converted to phen-
ols, dihydrodiols, glutathione, glucuronide, or sulfate
conjugates. It has been suggested that the harmful ef-
fects ofbenzo[al]pyrene are due to covalent interactions
ofelectrophilic metabolic intermediates, e.g., epoxides
and diolepoxides, with proteins and nucleic acids
(40,41). Cigarette smoke increases the activity of aryl
hydrocarbon hydroxylase in rat lung (42) and in human
alveolar macrophages (43). Okamoto et al. (44) dem-
onstrated that the aryl hydrocarbon hydroxylase activ-
ityinhamsterlunginstilledintratracheallywithtobacco
smoke condensate, marijuana smoke condensate, and
benzo[a]pyrene was significantly higher than that ob-
served inthe control. The amounts ofmanymetabolites
ofbenzo[alpyrene formed by rat lung microsomes (45)
and by isolated perfused rat lungs (46) are increased
after cigarette smoke exposure. Simberg et al. (47) in-
vestigated the stimulatory effect ofcigarette smoke on
the metabolism and covalent binding ofbenzo[a]pyrene
in the trachea ofthe rat. The activity ofaryl hydrocar-
bon hydroxylase was increased in the trachea of rats
exposed to cigarette smoke for 1 hr daily for either 1
or 10 days. However, the degree ofincrease in activity
was lowerinthe tracheathaninthe lung. Afterasingle
exposure, the activity in the trachea was at its highest
level 12 hr following exposure, but had returned to the
control level within 24 hr. The amounts of covalently
bound metabolites ofbenzo[a]pyrene were increased 2-
fold in nucleic acid and protein fractions ofthe trachea
when the rats were sacrificed 12 hr after a single cig-
arette smoke exposure. Simberg et al. concluded that
no change could be detected in the activity of epoxide
hydratase in the trachea and that repeated cigarette
smokeexposuresslightlyincreasedtheactivityofUDP-
glucuronosyltransferase both in the trachea and in the
lung.
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Effect of Cigarette Smoke on Angiotension
I Conversion in the Lung
Conversion of the inactive decapeptide, angiotensin
I, to the octapeptide pressor agent, angiotensin II, oc-
curs primarily inthe lung(48,49). Therehave been sev-
eral reports of altered pulmonary conversion of angi-
otension I by changes in pulmonary oxygenation (50)
and hemodynamics (51), and altered plasma coverting
enzymeactivityhasbeenreportedinpatientswithspon-
taneous pneumothorax (52), sarcoidosis (53), and other
chronic lung diseases (54). In view of the observation
that, in spite of the acute pressor effects of smoking,
smokers ingeneraltendtoward slight hypotension with
respect to nonsmokers (55), it might be interesting to
examinethepossibleeffectofcigarettesmokeinhalation
on the conversion of angiotensin I to angiotensin II in
the isolated perfused lung.
Hagedron et al. (56)investigated the effect oftobacco
smoke on the biotransformation ofangiotensin I in the
isolatedperfusedrabbitlung. Lungswereperfusedwith
Krebs-Ringer bicarbonate buffer in a nonrecirculation
fashion at a flow of 20 or 28 mL/min. The lung prepa-
ration was permitted to stabilize for 15 to 30 min prior
to angiotensin I administration. Angiotensin I was ad-
ministered at a rate of 81 ng/min in a volume of 0.27
mL/min, via a cannula placed in the perfusion fluid flow
in the pulmonary artery. One mL perfusate samples
were collected in polypropylene tubes at the outflow
from the left atrial cannula at convenient intervals fol-
lowing initiation of the angiotensin I infusion. Smoke
was administered to the lung preparation 15 min after
initiation of the angiotensin I infusion. Puffs of 2 sec
duration and 40 mL volume were generated once per
minute from University ofKentucky2RI Research Cig-
arettes. Four such puffs were delivered to the lung in
each smoke exposure. Angiotensin II concentrations in
perfusate fractions were determined by radioimmu-
noassay, usingangiotensinIIantiserumandangiotensin
II tracer. Under the conditions of these experiments,
the extent ofangiotensin I conversion to angiotensin II
was between 37 and 63% for various lungpreparations,
and concentration of angiotensin II in perfusate at
steady state before and after smoke administration did
not show any significant change. It is therefore con-
cluded that the acute administration ofcigarette smoke
does not significantly alterpulmonary conversion ofan-
giotensin I to angiotensin II.
Bakhle et al. (57) investigated the effects ofcigarette
smoke on the metabolism of vasoactive hormones in
isolated lungs ofmale adult Wistar rats. Rats were ex-
posedtocigarette smokein aninhalation chamber. Dur-
ing 1hr, theratsinhaledthesmokefromfivecommercial
cigarettes, each of them containing 1 mg nicotine and
16 mg tar, as quoted by the manufacturer. The rats
were exposed once (1 day exposure) ordaily for 10 con-
secutive days (10 days ofexposure). About 20 hr after
the last exposure, rats were anesthetized with sodium
pentobarbitone (50 mg/kg, IP), and the lungs were re-
moved and prepared for perfusion. Oxygenated,
warmed Krebs solution was pumped through the pul-
monarycirculationat8mL/min. Theeffluentsuperfused
two assay tissues (rat colon) arranged in cascade below
the lung. The contractions ofthe tissues were recorded
on a potentiometric recorder via Harvard smooth mus-
cle transducers and auxotonic levers. Percent conver-
sion of angiotensin I to angiotensin II was calculated
fromtheserecords, andtheyconcludedthatangiotensin
I conversion was increased after 1 day exposure but
after 10 days exposure conversion returned to normal.
Tivonen(58)investigatedtheeffectofnicotineinstead
of cigarette smoke on conversion of angiotensin I in
isolated lungs ofmale adult Wistar rats. Rats were ex-
posed to SC injections ofnicotine base (1 mg/kg). When
the rats were exposed to nicotine only once and 50 ng
ofangiotensin I was injected as abolus intothe isolated
perfused lungs from these animals about 24 hrafterthe
nicotine exposure, there was no difference in the acti-
vation ofangiotensin I toangiotensin IIwhencompared
with the lungs from sham treated or control animals.
When the nicotine exposure was repeated during 10
consecutive days, there was an increased formation of
angiotensin II from angiotensin I when compared with
control rats. There was, however, no difference be-
tweenthelungsfrom 10daysshamand 10daysnicotine-
exposed rats. This suggests that the increased forma-
tionofangiotensin IImighthavebeendueatleastpartly
to factors other than nicotine, for instance, to the ac-
tivation of renin-angiotensin system because of the
stressingofthe animals. Theseresults differfromthose
of Balkhle et al (57). The discrepancy in the results of
these two studies suggests that nicotine was not the
factor in cigarette smoke which caused the metabolic
changes in the cigarette smoke exposure experiments.
However, it must be taken into account that in the
present worknicotine reached the lungs viacirculation,
thus affecting first the endothelial cells responsible for
angiotensin II conversion (59); much lower amounts of
IV nicotine caused endothelial injury (60). When ciga-
rette smoke is inhaled, nicotine is partly transferred
through the alveolar wall and it could thus have better
access to the enzymes metabolizing prostaglandin E2.
The activation of angiotensin I conversion after ciga-
rette smoke inhalation might also be secondary to the
changed prostaglandin metabolism. Ercan et al. (61)
have proposed that when one ofthe enzymes, PG-syn-
thetase or converting enzyme, is inhibited, the other is
simultaneously activated.
As previously described (6), we also investigated the
effects ofcigarette smokingon serumangiotensin I con-
verting enzyme (ACE) activity in healthy volunteers.
Figure 10 shows the effect of cigarette smoking on
serum ACE level. Serum ACE activity showed a sig-
nificant increase immediately after smoking and re-
turned to the control level20 min aftersmoking. Inthis
experiment we did not measure conversion ofangioten-
sin I to angiotensin II. Ifthe increase ofACE activity
means increase of conversion of angiotensin I to angi-
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FIGURE 10. Effect of cigarette smoking on serum level ofACE.
otensin II, the events at the pulmonary endothelial cell
membrane couldbeaffectedbyarelativelydistantstim-
ula, i.e., smoke in the airways.
creased during cigarette smoke ventilation, and the
amount of metabolites of 5-HT in the perfused lungs
was also decreased by cigarette smoke ventilation, al-
though the total amount of radioactivity in the lung
tissuewas not significantly changed. Thedecreasedpul-
monary inactivation of 5-HT may cause increased cir-
culation levels of5-HT, which would explain some car-
diovascular changes during smoking.
As previously described (6), we also investigated the
effect ofcigarette smoking on plasma level ofserotonin
in 23 healthy volunteers (20 men and 3 women). All of
the volunteers wereheavysmokers (20to40cigarettes/
day) for 5 to 20 years. The volunteers stopped smoking
at least 12 hr before the testing began. When testing
began, men smoked five cigarettes and women smoked
three cigarettes within 10 min. Figure shows changes
ofplasma serotonin level in 23 healthy volunteers after
cigarette smoking. Plasmaserotoninlevelshowedasig-
nificant decreaseimmediatelyaftersmokingand stayed
lower than normal for more than 20 min. The discrep-
ancy in the results of this study and the one by Karhi
et al. might come from the difference ofanimal species
and from the difference ofexperiment method, i.e., in
vitro or in vivo.
Although the lung is thought to be the major site of
serotonin inactivation, blood platelets, liver, and other
tissues can also bind or inactivate this amine. Further
studies are needed inthisfield beforetherole ofaltered
serotonin metabolism in the course ofcigarette smoke-
induced cardiovascular alterations can be evaluated.
Effect of Cigarette Smoking on Serotonin
(5-HT) Metabolism in the Lung
Pre-exposure ofratstocigarettesmokefor1 hreither
once or daily during 10 consecutive days did not affect
the metabolism of 5-hydroxytryptamine (5-HT) in iso-
lated perfused lung (62). However, there is evidence
that cigarette smoke may change 5-HT metabolism.
Perfusion of isolated lungs of the rat (63) and guinea
pig (64) with anoxic solution partially inhibits both the
5-HTuptake andthe oxidationof5-HT. Cyanide, acom-
ponent of cigarette smoke, also inhibits the uptake of
5-HT (64). In mouse skin, cigarette smoke exposure
inhibits 5-HT-specific monoamine oxidase activity and
increases 5-HT uptake (65).
Karhietal. (66)investigatedwhethercigarettesmoke
ventilation during perfusion of isolated rat lungs has
any effect on the pulmonary metabolism of 5-HT. 14C-
5-HT was infused into the pulmonary circulation ofiso-
lated perfused rat lungs. The nonrecirculating perfu-
sion effluent was collected during the 5-HT infusion in
three consecutive 1-min fractions. The amount of me-
tabolites of 5-HT was determined from the perfusion
effluent and from the perfused lungs. The amount of
metabolites of 5-HT in the perfusion effluent was de-
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Effect of Cigarette Smoking on Histamine
Metabolism in the Lung
Histamine was not removed by the pulmonary cir-
culation in anesthetized dogs, as the biological activity
ofblood sampled from the femoral artery was the same
whether histamine was infused into the superior vena
cava or into the base ofthe ascending aorta or left ven-
tricle (67). Although histamine was not removed in the
pulmonary circulation in whole lungs, it was readily
inactivated in lung slices or in chopped or homogenized
lung preparations from man (68), cat (69), rabbit (70),
guinea pig, and rat (71). The main metabolite formed
was species dependent and reflected the types of his-
tamine-metabolizing enzymesinthelungofeach species
(72) and their concentrations in the lung. The lack of
histamine inactivation in whole lung might be due to
the absence ofa transport mechanism for histamine in
the pulmonary circulation. The lunghas the capacity to
synthesizehistamine, ashistidinedecarboxylaseispres-
entinlungtissue (73). Histamine ispresent in thelungs
ofmost species; the amount is generally related to the
population of mast cells. These cells can take up and
store histamine, but uptake is a slow process and not
likely to contribute to the removal ofexogenous hista-
mine during a single passage through the pulmonary
circulation.
The release ofhistamine from human asthmatic lung
and bronchial tissue during challenge with specific an-
tigen was demonstrated by Schild et al. (74) and con-
firmed by Brocklehurst (75), who perfused and chal-
lenged lung segments from subjects with allergies and
showed the release ofboth histamine and slow-reacting
substance of anaphylaxis (SRS-A).
The release ofhistamine has been postulated to occur
in two experimental situations. First, during anoxemia
in a heart-lung preparation, the increase in force ofmy-
ocardial contraction can be blocked by the previous
administration ofthe antihistaminic drug (76). Second,
the bronchoconstrictor response in the intact dog fol-
lowing the inhalation of tobacco smoke, the bronchial
arterial injection of nicotine, or the pleural application
ofnicotine solution can be simulated bythe correspond-
ing administration of histamine, so the release of his-
tamine was proposed as the basic mechanism for the
bronchoconstriction induced by tobacco and nicotine.
Aviado et al. (60) investigated the release ofhistamine
during inhalation of cigarette smoke and anoxemia in
the heart-lung and intact dog preparation. They sug-
gested that there was a definite release of histamine
during the period of anoxia, and that the initial bron-
choconstriction initiated by inhalation of cigarette
smoke might induce a localized state ofanoxia, and this
in turn might cause the release of histamine.
As previously described (6), we investigated the ef-
fect of cigarette smoking on plasma level of histamine
in healthy volunteers. Figure 12 shows the change of
plasma histamine level in 23 healthy volunteers by cig-
arette smoking. Plasma histamine level showed a sig-
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FIGURE 12. Change of plasma histamine level before (control), im-
mediately after (0 min), and 20 min after cigarette smoking.
nificant decrease immediatelyaftersmokingand stayed
lower than normnal for more than 20 min. These results
suggest that plasma histamine levels were markedly
decreased after smoking by either the elevation ofhis-
taminase activity or increase of histamine uptake in-
duced by nicotine and other components of tobacco
smoke.
Effect of Cigarette Smoke and Related
Substances on Prostaglandin and
Thromboxane Metabolism in the Lung
Any contemporary account ofmetabolic functions of
the lung might be incomplete without a discussion of
prostaglandin (PG) metabolism. The prostaglandins
possess abewilderingspectrumofphysiologicalandbio-
chemicalactivitiesinthevariousmammaliantissuesand
organs, including heart and lung. It is well known that
the lung possesses extremely efficient enzymatic ma-
chinery for the rapid conversion of prostaglandins to
inactive metabolites, and that the lung also has an abil-
ity to synthesize prostaglandins. This is surprising con-
sidering that the lung contains a relative abundance of
PG synthetase and considering that prostaglandins are
readily released from perfused lungs by such diverse
stimuli as vasoactive peptides (78), phospholipase A
(79), anaphylactic shock (80), histamine (81), serotonin
and tryptamine (82), hypoxia (83), and mechanical ven-
tilation (84).
Prostacyclin is a product of arachidonic acid metab-
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olism generated by the vessel wall of all mammalian
species, including man. Prostacyclin is a potent vaso-
dilator and inhibitor ofplatelet aggregation. It inhibits
platelet aggregation through stimulation of adenylate
cyclase, which leads to an increase in cyclic AMP in the
platelets. The enzyme which synthesizes prostacyclin is
mainly located in the endothelial layer of the vascular
wall (85).
In blood platelets, arachidonic acid is converted by
the enzyme thromboxane synthetase to a potent vaso-
constrictor and proaggregation substance, thrombox-
ane A2 (86). Therefore, arachidonic acid is metabolized
in the vessel wall and in platelets to potent substances
withopposingbiologicalactivities. Thebalancebetween
thromboxane A2 and prostacyclin might be important
in the control ofthe pulmonary circulation.
Because blood platelets appear to play a central role
in the initiation ofarterial thrombosis, the difference in
aggregation behavior in platelets from smokers and
nonsmokers seems to be important. It is known that
smoking induces enhancement ofplatelet function (87).
Evidence supportingthis idea includes an association of
smoking with increased ADP-induced platelet aggre-
gation (88), a shortening of platelet survival (89), and
increased thromboxane synthesis (90). In addition,
there is some evidence that smoking might exert its
action by reducing vascular prostacyclin (PGI2) synthe-
sis (91). Burghuber et al. (92) investigated the response
of platelets to exogenous PGI2 in chronic smokers and
nonsmokers before and after smoking two cigarettes
and concluded that decreased platelet sensitivity to
PGI2 might be an important contributing factor to the
altered platelet function observed in patients with ath-
erosclerosis.
Hagedron et al. (93) studied the effect of tobacco
smoke on uptake and metabolism of prostaglandin F2a
in isolated perfused rabbit lungs. Male white rabbits
weighing 3 to 4 kg were anesthetized with sodium pen-
tobarbital at a dose of40 mg/kg and were treated with
heparin at a level of 1000 U/kg. Blood was withdrawn
bycardiac puncture; the lungs and heartwereremoved;
andthepulmonaryartery, leftatrium, andtracheawere
cannulated. The lung preparation was then suspended
in an artificial thorax. Respirator controls were set to
provide 50 respirations per min, with 30 mL stroke
volume. Perfusate flow was at a constant hydrostatic
pressure of23 cm, and flow prior to PGF2. administra-
tion was stable at 200 to 300 mL/min. PGF2a was ad-
minstered to the lung both as a bolus dose and as a
constant rate infusion. In the bolus dose studies,
PGF2J[9-3H(N)] was combined with unlabeled PGF2a
and was administered as a bolus dose of 0.28 to 0.42
,umole (15-30° ,uCi) in 0.25 to 0.4 mL of normal saline.
In the constant infusion studies, PGF? was adminis-
tered to the lung via an infusion pump which delivered
0.17 nmole PGF2a(1.59 ,uCi)/min in an infusion fluid vol-
ume of 0.53 mL/min. In these studies, smoke was ad-
ministered to the lung after 30 min from starting per-
fusion without altering the constant rate of PGF2o
infusion. In smoke exposure studies, puffs of2-sec du-
ration and 40 mL volume were generated once per min-
ute from University of Kentucky 2RI Research Ciga-
rettes. Four such puffs were delivered to the lung in
each smoke exposure. These studies showed that there
was no effect ofcigarette smoke on uptake and metab-
olism of PGF2c. in isolated perfused rabbit lungs.
Bakhle et al. (57) studied the effects of cigarette
smoke on the metabolism of vasoactive hormones in
isolated rat lungs. They demonstrated that inactivation
ofPGE2 was decreased after 1 day exposure and after
10 days exposure, there was a further decrease that
could not be attributed to smoke alone. PGE2 metabo-
lism in rat lung is not transport limited, and this me-
tabolism was unequivocally decreased after 1 day ex-
posure to cigarette smoke, suggesting a decreased
activity of 15-hydroxyprostaglandin dehydrogenase
(PGDH), therate-limitingenzymeinPGE2degradation
in lung. Although the change is numerically small, it
representsadoublingofthePGE2enteringthesystemic
arterialcirculation. The changesoccurringafter 10 days
exposure can not be safely attributed to smoke expo-
sure, as survival of PGE2 increased in both sham- and
smoke-exposed animals.
Tivonen (58) studied the effect ofnicotine on the me-
tabolism of PGE2 in isolated rat lungs. Usually, about
95% of PGE2 (250-500 ng) was inactivated during one
passage through the pulmonary circulation, but expo-
sure ofrats to nicotine for 1 or 10 days did not change
the ability of their lungs to inactivate PGE2. The dis-
crepancy in the results of these two studies suggests
thatnicotinewasnotthefactorincigarettesmokewhich
causedthe metabolic changes inthe experiments. When
cigarette smokeisinhaled, nicotineispartlytransferred
through the alveolar wall, and it could have better ac-
cess to the enzymes metabolizing PGE2. Berry et al.
(94) also demonstrated that nicotine aerosol inhalation
increased prostaglandin efflux from isolated rat lungs,
and in their preliminary experiments, PGF2at break-
downwasinhibited inratlunghomogenatesbynicotine.
Effect of Cigarette Smoke on Protein
Synthesis in the Lung
Garrett et al. (95) studied the effect of cigarette
smoke on protein synthesis in the lungs of Sprague-
Dawley rats. In vivo exposure of lung to cigarette
smoke results in suppression of protein synthesis by
pulmonary tissue. Lungs from sham control rats syn-
thesize protein at a rate of 0.97 + 0.16 nmole proline/
mL DNA/min. Pulmonary protein synthesis during ex-
posure to 45 to 60 puffs of smoke is inhibited by 60 to
80%. The component of smoke which inhibits protein
synthesis is not significantly removed by Cambridge
filters which adsorb particulate matter or by charcoal
filters which adsorb many gases. Carbon monoxide is
notremovedbyeithertypeoffilter. Atthelevelpresent
in cigarette smoke, CO produces a marked protein in-
hibitory effect comparable to that of cigarette smoke
(96). These results suggest that CO might be a com-
ponent in cigarette smoke that interferes with pulmo-
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nary protein synthesis. Inhibition of protein synthesis
in the lung of intact animals might result in defective
structural composition and could render the lung sus-
ceptible to injuries inflicted by bacteria or other envi-
ronmental agents. Garret et al. suggested that emphy-
sema might be due to proteolysis ofthe lung at a time
when it was unable to repair itself adequately through
protein synthesis.
Effect of Cigarette Smoke Exposure on
Testosterone Metabolism in the Lung
Hartialaetal. (97)investigatedtheeffectsofcigarette
smoke exposure on testosterone metabolism in the iso-
lated perfused rat lung. They exposed rats to cigarette
smoke daily for 1 hr for 5 consecutive days. The me-
tabolism of [4-'4C]-testosterone by isolated perfused
lungs was studied on the sixth day. Slightly diluted rat
blood, containing the radioactive substrate, was used
astheperfusionfluid. Comparedtosham-exposurerats,
the formation of reduced metabolites, dihydroxyster-
oids, was less, and the metabolism of testosterone di-
minished aftercigarette smoke exposure. Aftertheper-
fusion, the amount ofpolar nonconjugated metabolism
was significantly higher in the smoke-exposed lung tis-
sue than in the control lungs, and no conjugate forma-
tion was observed. These researchers suggested that
the decrease in the formation of reduced metabolites
was due to an inhibition of the 4-ene-5a-reductase ac-
tivity. The present study clearly calls for further in-
vestigations on the effects of cigarette smoking on the
steroid metabolism.
Effect of Cigarette Smoke Exposure on
Cyclic Nucleotides Metabolism in the
Lung
Nitroglycerin, nitroprusside, nitrosamines, sodium
azide, nitric oxide, peroxides, and the hydroxyl radical
activate guanylate cyclase to convert guanosine tri-
phosphate into cyclic GMP. Although the mechanism of
enzyme activation is not clear, it is apparent that bio-
logical oxidation and radical formation are very impor-
tant factors in the function of guanylate cyclase (98).
Based upon this information and the fact that nitric
oxide is an important gaseous constituent of tobacco
smoke, Arnold et al. (99) exposed lung tissue in vitro
and guanylate cyclase preparations from lung tissue to
an environment of pure (98%) cigarette smoke, and
showed prompt increases in cyclase activity and cyclic
GMP levels. In a variety ofmammalian systems, cyclic
GMP has been proposed to act as a mediator of tissue
proliferation (100), smooth muscle contraction and re-
laxation (101), and as a promoter of the inflammatory
response (102). Becausemanyoftheseactionshavebeen
applied to tissue cyclic GMP, it seems possible that the
activation ofguanylate cyclase and production ofcyclic
GMPmight be animportant pulmonary response tocig-
arette smoke.
Cigarette smoke is an extremely complex mixture of
particulate and gaseous materials. Veseley et al. (103)
have shown that hydrazine, a known carcinogen that is
a component ofcigarette smoke, is capable ofstimulat-
ing guanylate cyclase in vitro. Klass (104) studied
whether exposure of rats in vivo to tolerable levels of
cigarette smoke iscapable ofalteringlungcyclic GMP.
Adults rats were anesthetized with pentobarbital, and
ventilation with mixtures ofair and cigarette smoke at
10 cm H20 inspiratory pressure was achieved after a
tracheotomy was performed. Lungtissue samples were
taken at intervals during the 20-min expsoure period
and analyzed for levels ofcyclic adenosine 3', 5'-mono-
phoshate (AMP), and cyclic GMP. Blood carboxyhem-
oglobin (COHb) levels at 5 min and 15 min ofexposure
were high, but levels of COHb were sublethal. Lung
tissue cyclic AMP was unchanged with this exposure,
but cyclic GMP levels rose dramatically. Cyclic GMP
has been suggested to play a role in the action ofbron-
chialandtrachealsmoothmuscle (105), thoughtheexact
nature of this mechanism is unclear. It is possible to
speculate that an irritative response to cigarette smoke
triggers bronchial smooth muscle contraction with an
associated increase ofcyclic GMP. Cigarette smoke has
also been shown to induce pulmonary vascular constric-
tion which may be associated with increased level of
cyclic GMP. A similar response might equally accom-
pany bronchial gland secretion stimulated by cigarette
smoke (106). Barnett et al. (107) have demonstrated
increased levels ofcyclic GMP in the dog lungtissue by
histamine infusion, and Kaliner et al. (102) have dem-
onstrated cyclic GMP to be associated with increased
chemical mediator release from lung. It is possible that
the increase in lung cyclic GMP seen here is related to
inflammation associated with cigarette smoke inhala-
tion. Since changesincyclicGMPmetabolismhavebeen
associated with abnormalities in cellular growth
(100,103), it is possible that the increase in cyclic GMP
in tissues associated with components of cigarette
smoke might be related to the initiation of abnormal
cellular growth such as bronchogenic carcinoma.
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